(EVK) Evonik Industries - Ratings and Ratios
Specialty Additives, Nutrition Care, Smart Materials, Technology Infrastructure
EVK EPS (Earnings per Share)
EVK Revenue
| Risk via 10d forecast | |
|---|---|
| Volatility | 21.8% |
| Value at Risk 5%th | 34.4% |
| Relative Tail Risk | -3.92% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.71 |
| Alpha | -21.51 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.442 |
| Beta | 0.158 |
| Beta Downside | 0.414 |
| Drawdowns 3y | |
|---|---|
| Max DD | 34.13% |
| Mean DD | 11.17% |
| Median DD | 10.84% |
Description: EVK Evonik Industries November 04, 2025
Evonik Industries AG (XETRA:EVK) is a global specialty chemicals producer operating across six continents, organized into four business segments: Specialty Additives, Nutrition & Care, Smart Materials, and Technology & Infrastructure. The Specialty Additives division supplies performance-enhancing chemicals for polyurethane foams, paints, coatings, adhesives, and lubricants; Nutrition & Care delivers amino acids for animal feed, pharmaceutical intermediates, and medical-grade biocompatible materials; Smart Materials focuses on inorganic silicas, peroxides, catalysts, and high-performance polymers; while Technology & Infrastructure offers plant-level services such as energy management, digital production solutions, and logistics safety.
In FY 2023 Evonik generated €15.2 billion in revenue with an adjusted EBITDA margin of roughly 13.5%, reflecting strong demand for lightweighting solutions in the automotive sector and growth in high-value medical-device materials. A key economic driver is the ongoing raw-material price inflation, especially for petrochemical feedstocks, which compresses margins unless offset by pricing power or cost-saving initiatives. The specialty chemicals sector is also benefitting from sustainability trends, as customers increasingly seek low-VOC additives and recyclable polymer systems, positioning Evonik’s “green” product portfolio for incremental market share.
For a deeper quantitative dive, you may find the analyst tools on ValueRay useful to model EVK’s cash-flow sensitivity to raw-material cost swings.
EVK Stock Overview
| Market Cap in USD | 7,776m |
| Sub-Industry | Specialty Chemicals |
| IPO / Inception | |
| Return 12m vs S&P 500 | -25.2% |
| Analyst Rating | - |
EVK Dividends
| Dividend Yield | 8.30% |
| Yield on Cost 5y | 6.47% |
| Yield CAGR 5y | 0.43% |
| Payout Consistency | 96.7% |
| Payout Ratio | 86.0% |
EVK Growth Ratios
| CAGR 3y | -2.88% |
| CAGR/Max DD Calmar Ratio | -0.08 |
| CAGR/Mean DD Pain Ratio | -0.26 |
| Current Volume | 870.2k |
| Average Volume | 1124.5k |
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (424.0m TTM) > 0 and > 6% of Revenue (6% = 882.4m TTM) |
| FCFTA 0.02 (>2.0%) and ΔFCFTA -3.99pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 11.74% (prev 11.17%; Δ 0.57pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 1.32b > Net Income 424.0m (YES >=105%, WARN >=100%) |
| Net Debt (-379.0m) to EBITDA (1.93b) ratio: -0.20 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.45 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (461.5m) change vs 12m ago -0.96% (target <= -2.0% for YES) |
| Gross Margin 24.69% (prev 22.45%; Δ 2.24pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 74.92% (prev 74.74%; Δ 0.18pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 3.87 (EBITDA TTM 1.93b / Interest Expense TTM 214.0m) >= 6 (WARN >= 3) |
Altman Z'' 2.96
| (A) 0.09 = (Total Current Assets 5.60b - Total Current Liabilities 3.87b) / Total Assets 19.05b |
| (B) 0.39 = Retained Earnings (Balance) 7.50b / Total Assets 19.05b |
| (C) 0.04 = EBIT TTM 829.0m / Avg Total Assets 19.63b |
| (D) 0.76 = Book Value of Equity 7.96b / Total Liabilities 10.49b |
| Total Rating: 2.96 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 53.67
| 1. Piotroski 5.0pt = 0.0 |
| 2. FCF Yield 4.67% = 2.33 |
| 3. FCF Margin 3.21% = 0.80 |
| 4. Debt/Equity 0.45 = 2.40 |
| 5. Debt/Ebitda -0.20 = 2.50 |
| 6. ROIC - WACC (= -0.37)% = -0.46 |
| 7. RoE 4.75% = 0.40 |
| 8. Rev. Trend -77.39% = -5.80 |
| 9. EPS Trend 29.97% = 1.50 |
What is the price of EVK shares?
Over the past week, the price has changed by +1.44%, over one month by -2.42%, over three months by -14.96% and over the past year by -14.77%.
Is Evonik Industries a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of EVK is around 13.74 EUR . This means that EVK is currently overvalued and has a potential downside of -2.55%.
Is EVK a buy, sell or hold?
What are the forecasts/targets for the EVK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 18.1 | 28% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 15 | 6.1% |
EVK Fundamental Data Overview January 01, 1970
Market Cap EUR = 6.71b (6.71b EUR * 1.0 EUR.EUR)
P/E Trailing = 66.9048
P/E Forward = 19.9203
P/S = 0.4703
P/B = 1.0937
P/EG = 5.0637
Beta = 0.734
Revenue TTM = 14.71b EUR
EBIT TTM = 829.0m EUR
EBITDA TTM = 1.93b EUR
Long Term Debt = 3.59b EUR (from longTermDebt, last quarter)
Short Term Debt = 837.0m EUR (from shortTermDebt, last fiscal year)
Debt = 3.78b EUR (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -379.0m EUR (from netDebt column, last quarter)
Enterprise Value = 10.11b EUR (6.71b + Debt 3.78b - CCE 379.0m)
Interest Coverage Ratio = 3.87 (Ebit TTM 829.0m / Interest Expense TTM 214.0m)
FCF Yield = 4.67% (FCF TTM 472.0m / Enterprise Value 10.11b)
FCF Margin = 3.21% (FCF TTM 472.0m / Revenue TTM 14.71b)
Net Margin = 2.88% (Net Income TTM 424.0m / Revenue TTM 14.71b)
Gross Margin = 24.69% ((Revenue TTM 14.71b - Cost of Revenue TTM 11.08b) / Revenue TTM)
Gross Margin QoQ = 26.61% (prev 26.69%)
Tobins Q-Ratio = 0.53 (Enterprise Value 10.11b / Total Assets 19.05b)
Interest Expense / Debt = 1.48% (Interest Expense 56.0m / Debt 3.78b)
Taxrate = 35.42% (68.0m / 192.0m)
NOPAT = 535.4m (EBIT 829.0m * (1 - 35.42%))
Current Ratio = 1.45 (Total Current Assets 5.60b / Total Current Liabilities 3.87b)
Debt / Equity = 0.45 (Debt 3.78b / totalStockholderEquity, last quarter 8.49b)
Debt / EBITDA = -0.20 (Net Debt -379.0m / EBITDA 1.93b)
Debt / FCF = -0.80 (Net Debt -379.0m / FCF TTM 472.0m)
Total Stockholder Equity = 8.93b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.23% (Net Income 424.0m / Total Assets 19.05b)
RoE = 4.75% (Net Income TTM 424.0m / Total Stockholder Equity 8.93b)
RoCE = 6.62% (EBIT 829.0m / Capital Employed (Equity 8.93b + L.T.Debt 3.59b))
RoIC = 5.55% (NOPAT 535.4m / Invested Capital 9.64b)
WACC = 5.92% (E(6.71b)/V(10.49b) * Re(8.72%) + D(3.78b)/V(10.49b) * Rd(1.48%) * (1-Tc(0.35)))
Discount Rate = 8.72% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -81.65 | Cagr: -0.48%
[DCF Debug] Terminal Value 76.22% ; FCFE base≈805.6m ; Y1≈824.5m ; Y5≈916.2m
Fair Price DCF = 30.58 (DCF Value 14.25b / Shares Outstanding 466.0m; 5y FCF grow 2.21% → 3.0% )
EPS Correlation: 29.97 | EPS CAGR: 11.53% | SUE: -0.22 | # QB: 0
Revenue Correlation: -77.39 | Revenue CAGR: -11.38% | SUE: -2.21 | # QB: 0